Last edition
News about "Tanabe Pharma Corporation"
Tolerance Bio Licenses Anti-IL-33 Antibody TLB-33 from Tanabe Pharma
Tolerance Bio plans to advance TLB-33 into Phase 2 development to evaluate its potential in preserving thymic function and supporting immune resilience.
Tanabe Pharma Corporation | 29/09/2026 | By News Bureau
LEO Pharma has agreed to acquire worldwide rights to Tanabe Pharma’s oral MC1R agonist dersimelagon for up to USD 435 million in upfront and near-term milestones, strengthening its rare dermatology pipeline for EPP and XLP.
Tanabe Pharma Corporation | 19/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy